Constant Voltage Iontophoresis Technique to Deliver Terbinafine via Transungual Delivery System: Formulation Optimization Using Box-Behnken Design and In Vitro Evaluation.
Box–Behnken model
antifungal study
enhancer
low voltage iontophoresis
nail permeation
onychomycosis
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
15 Oct 2021
15 Oct 2021
Historique:
received:
17
09
2021
revised:
11
10
2021
accepted:
12
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Topical therapy of antifungals is primarily restricted due to the low innate transport of drugs through the thick multi-layered keratinized nail plate. The objective of this investigation was to develop a gel formulation, and to optimize and evaluate the transungual delivery of terbinafine using the constant voltage iontophoresis technique. Statistical analysis was performed using Box-Behnken design to optimize the transungual delivery of terbinafine by examining crucial variables namely concentration of polyethylene glycol, voltage, and duration of application (2-6 h). Optimization data in batches (F1-F17) demonstrated that chemical enhancer, applied voltage, and application time have influenced terbinafine nail delivery. Higher ex vivo permeation and drug accumulation into the nail tissue were noticed in the optimized batch (F8) when compared with other batches (F1-F17). A greater amount of terbinafine was released across the nails when the drug was accumulated by iontophoresis than the passive counterpart. A remarkably higher zone of inhibition was observed in nails with greater drug accumulation due to iontophoresis, as compared to the passive process. The results here demonstrate that the optimized formulation with low voltage iontophoresis could be a viable and alternative tool in the transungual delivery of terbinafine, which in turn could improve the success rate of topical nail therapy in onychomycosis.
Identifiants
pubmed: 34683985
pii: pharmaceutics13101692
doi: 10.3390/pharmaceutics13101692
pmc: PMC8538220
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Abdulaziz City for Science and Technology
ID : 12-MED3163-06
Références
Pharmaceutics. 2019 May 28;11(6):
pubmed: 31141993
Photochem Photobiol. 2012 May-Jun;88(3):512-22
pubmed: 22313493
Drug Dev Ind Pharm. 2013 May;39(5):807-15
pubmed: 23057692
Int J Pharm. 2009 Jun 22;375(1-2):22-7
pubmed: 19481686
J Pharm Sci. 2009 May;98(5):1788-96
pubmed: 18781625
Materials (Basel). 2019 Mar 28;12(7):
pubmed: 30925734
J Fungi (Basel). 2018 Jul 24;4(3):
pubmed: 30042327
Pharm Res. 2009 Sep;26(9):2194-201
pubmed: 19582550
Am J Clin Dermatol. 2003;4(1):39-65
pubmed: 12477372
Pharm Res. 2013 Jun;30(6):1652-62
pubmed: 23462934
PLoS One. 2021 Mar 19;16(3):e0248857
pubmed: 33739996
J Clin Aesthet Dermatol. 2015 Nov;8(11):38-42
pubmed: 26705439
Recent Pat Drug Deliv Formul. 2019;13(3):203-218
pubmed: 31663846
J Clin Aesthet Dermatol. 2019 Oct;12(10):29-34
pubmed: 32038746
J Pharm Pract. 2017 Apr;30(2):245-255
pubmed: 26873506
J Pharm Pharmacol. 2009 Apr;61(4):431-7
pubmed: 19298688
Mycopathologia. 2017 Feb;182(1-2):127-141
pubmed: 27502503
Int J Pharm. 2002 Apr 2;236(1-2):1-26
pubmed: 11891066
J Mater Chem B. 2019 Jan 21;7(3):373-383
pubmed: 32254724
Molecules. 2020 Nov 26;25(23):
pubmed: 33256033
Int J Cosmet Sci. 2014 Oct;36(5):398-411
pubmed: 24888698
Pharmaceutics. 2021 May 24;13(6):
pubmed: 34073997
J Drug Target. 2014 Nov;22(9):769-89
pubmed: 24964054
Expert Opin Drug Deliv. 2012 Jan;9(1):91-103
pubmed: 22149385
Drug Deliv. 2019 Dec;26(1):1167-1177
pubmed: 31738083
Polymers (Basel). 2019 Oct 16;11(10):
pubmed: 31623262
Cochrane Database Syst Rev. 2017 Jul 14;7:CD010031
pubmed: 28707751
Curr Drug Deliv. 2010 Dec;7(5):407-14
pubmed: 20955143
Pharmaceutics. 2020 Sep 20;12(9):
pubmed: 32962195
J Mycol Med. 2020 Jun;30(2):100949
pubmed: 32234349
Pharmaceutics. 2018 Dec 13;10(4):
pubmed: 30551601
Drug Dev Ind Pharm. 2012 Aug;38(8):901-11
pubmed: 22149347
Molecules. 2021 Mar 16;26(6):
pubmed: 33809569
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972-1990
pubmed: 32239567
Int J Pharm. 2020 Aug 30;586:119499
pubmed: 32505580
AAPS J. 2021 Jan 13;23(1):25
pubmed: 33439400
Med Mycol. 2017 Jul 1;55(5):461-475
pubmed: 27703019
J Liposome Res. 2017 Dec;27(4):283-292
pubmed: 27558522
J Pharm Sci. 2009 Nov;98(11):4264-71
pubmed: 19363796
J Adv Res. 2016 May;7(3):453-61
pubmed: 27222750
J Am Acad Dermatol. 2019 Apr;80(4):835-851
pubmed: 29959961
Expert Opin Emerg Drugs. 2014 Dec;19(4):489-95
pubmed: 25401504
F1000Res. 2019 Jun 25;8:
pubmed: 31297182
AAPS PharmSciTech. 2020 Jan 14;21(2):67
pubmed: 31938980
Pharmaceutics. 2020 Mar 05;12(3):
pubmed: 32151015
Pharmaceutics. 2018 Sep 11;10(3):
pubmed: 30208659
Pharm Nanotechnol. 2019;7(1):24-38
pubmed: 31092174
J Toxicol. 2017;2017:6746989
pubmed: 28261269
Recent Pat Inflamm Allergy Drug Discov. 2020;14(1):32-45
pubmed: 31738146
J Fungi (Basel). 2019 Sep 04;5(3):
pubmed: 31487828
Curr Drug Res Rev. 2021;13(1):25-35
pubmed: 32735534
Drug Deliv. 2006 May-Jun;13(3):175-87
pubmed: 16556569
J Control Release. 2015 Feb 10;199:132-44
pubmed: 25481439
J Pharm Sci. 2009 Nov;98(11):4130-40
pubmed: 19340887
Sci Rep. 2021 Jun 17;11(1):12789
pubmed: 34140577
Drug Dev Ind Pharm. 2011 Oct;37(10):1253-8
pubmed: 21457120